نتایج جستجو برای: relapsing remitting multiple sclerosis

تعداد نتایج: 791996  

1998
Peter J H Jongen Karel J B Lamers Wim H Doesburg Wim A J G Lemmens Otto R Hommes

Objectives—To find whether CSF analysis may diVerentiate between relapsingremitting and secondary progressive multiple sclerosis. Methods—In 17 patients with relapsingremitting and 16 patients with secondary progressive multiple sclerosis, all without current or recent relapses, albumin CSF: peripheral blood ratio, mononuclear cell number, CD4+, CD8+, and B1+ subsets, CD4+:CD8+ ratio, IgG, IgG ...

Journal: :Journal of Neuroimmunology 2017
Simona Rolla Stefania Federica De Mercanti Valentina Bardina Dana Horakova Mario Habek Ivan Adamec Eleonora Cocco Pietro Annovazzi Anton Vladic Francesco Novelli Luca Durelli Marinella Clerico

Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell...

Journal: :Expert opinion on pharmacotherapy 2003
Sheila A Doggrell

In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were fewer new lesions/patient with natalizumab (0.7 and 1.1 with natalizumab 3 and 6 mg/kg every 28 days, respectively) than in the placebo group (9.6 new lesions/patient) over 6 months. There were also fewer relapses in the natalizumab groups than the placebo group. However, there were no changes in...

2012
Raphael Schneider

Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...

Journal: :Neurology 2012
Raphael Schneider Nathalie Arbour

Raphael Schneider, MD Nathalie Arbour, PhD The topic of this Journal Club is a study by Bielekova et al.,1 who assessed whether daclizumab monotherapy reduces contrast-enhancing lesions (CEL) in patients with relapsing-remitting multiple sclerosis (RRMS). Furthermore, they evaluated the effects of daclizumab on clinical outcome measures and on NK cell populations in the CSF and blood of treated...

Background: Multiple Sclerosis (MS), as one of the most common neurological diseases of the central nervous system, is associated with various cognitive impairments. The purpose of this study was the investigation and comparison of the information processing speed between various clinical subtypes of multiple sclerosis and compared to healthy individuals. Methods: In this cross-sectional study...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید